Tablet Computer Use at the Bedside in a New Patient/Family Education Program.

This article discusses various educational interventions implemented in a new patient/family education program at the University of South Alabama Children's &Women's Hospital in Mobile, Alabama, for patients and family members of those newly diagnosed with pediatric cancer and other chronic illnesses. Tablet computers were made available to access reputable, easy to understand health resources during the educational processes upon diagnosis and continued treatment at the hospital. MedlinePlus, Patient Education Institute's X-Plain videos and other National Library of Medicine resources were available at the bedside and while receiving chemotherapy infusions. Surveys were developed to determine the efficacy of the educational interventions. PMID: 31708714 [PubMed]
Source: Journal of Hospital Librarianship - Category: Databases & Libraries Tags: J Hosp Librariansh Source Type: research

Related Links:

We present two cases which are specific for unusual location of Burkitt lymphoma in the colon and stomach, in immunocompetent patients with negative Epstein-Barr virus tests. Also, one of the patients presented is one of the oldest ever reported with abdominal Burkitt lymphoma, while the other patient is an example of diagnostic difficulties in distinguishing Burkitt lymphoma from similar lymphomas. Due to the rapidly growing tumors and urgent need for cytoreductive surgery, it is crucial to consider the diagnosis of Burkitt lymphoma even in atypical localizations or absence of the common risk factors associated with Burki...
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
Authors: Topolovec Z, Horvat T, Vidosavljević D, Šijanović S, Müller-Vranješ A, Ugljarević M, Milojković D, Topolovec S Abstract The aim of this retrospective study was to present the impact of successful optimal cytoreductive therapy on the overall prognosis of ovarian cancer treatment. Several factors were analyzed, including clinical (stage, age and parity), histopathologic/cytological (histologic type and grade of tumors, cytological findings of ascites or peritoneal washout), and therapeutic (surgery performed with the degree of cytoreduction, adjuvant chemotherapy and response to therap...
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
Authors: Iorga RA, Bratu OG, Marcu RD, Constantin T, Mischianu DLD, Socea B, Gaman MA, Diaconu CC Abstract Patients with cancer-associated venous thromboembolism (VTE) represent a real challenge in clinical practice. Patients with cancer have a greater risk both of VTE and bleeding. There are only a few studies regarding the therapeutic approach of VTE in patients with cancer, especially after cancer surgery, and on thromboprophylaxis during chemotherapy. Many of the anticoagulation therapy recommendations for cancer patients are extrapolated from trials that are not conducted in cancer cohorts. It is essential to ...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
ConclusionTargeted axillary dissection is a feasible technique following excellent response to NACT in selected patients with limited volume ALN metastasis, at diagnosis. The identification of the positive ALN during surgery is vital and the IR can be improved by clipping the node prior to NACT and wire guided localisation at the time of surgery.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
This study aims to analyse the outcomes and related prognostic factors of IRE for Asian patients with LAPC.Materials and methodsFrom 2012 to 2017, this prospective trial for using IRE through surgical approaches for LAPC was conducted in 11 medical centres in Asia. All related and treatment outcomes were analysed from a prospective database.ResultsSeventy-four patients were enrolled. Thirty complications occurred in thirteen (17.6%) patients without mortality. The electrode placement direction (anteroposterior vs. craniocaudal, HR = 14.2, p 
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Conditions:   Esophageal Adenocarcinoma;   Gastric Adenocarcinoma Intervention:   Other: ChemoFit exercise prehabilitation intervention Sponsors:   Newcastle-upon-Tyne Hospitals NHS Trust;   Newcastle University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Atezolizumab;   Drug: Placebo;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Carboplatin Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This is a common scenario.1 The goal: maximize freedom from progression but minimize late risks. For a young woman, the main potential late risks secondary to radiation are breast cancer and cardiovascular disease. The main potential late risks from the escalation of chemotherapy are secondary myelodysplastic syndrome and infertility.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
Authors: Takamaru H, Yoshinaga S, Takisawa H, Oda I, Katai H, Sekine S, Taniguchi K, Saito Y Abstract Background/Aims: The accurate assessment of the depth of invasion of early gastric cancer (EGC) is critical to determine the most appropriate treatment option. However, it is difficult to distinguish shallow submucosal (SM1) invasion from deeper submucosal (SM2) invasion. We investigated the diagnostic performance of endoscopic ultrasonography (EUS) using a miniature probe for EGC with suspected SM invasion. Methods: From April 2008 to June 2018, EGCs with suspected SM invasion were analyzed retrospectively. Th...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Roche the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Children | Computers | Databases & Libraries | Education | Hospitals | Pediatrics | Universities & Medical Training | Women